The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Risk factor migration and survival: Analysis from international dataset of 3,748 metastatic renal cell carcinoma (mRCC) patients treated on clinical trials.
S. Patil
No relevant relationships to disclose
J. Manola
No relevant relationships to disclose
P. Elson
No relevant relationships to disclose
W. Bro
No relevant relationships to disclose
S. Negrier
No relevant relationships to disclose
B. Escudier
Consultant or Advisory Role - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer; Roche
Honoraria - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer; Roche
R. M. Bukowski
Consultant or Advisory Role - Genentech; GlaxoSmithKline; Novartis; Pfizer
Honoraria - Genentech; Novartis; Pfizer
R. J. Motzer
No relevant relationships to disclose